Everett Harris & Co. CA Sells 15,417 Shares of Novo Nordisk A/S (NYSE:NVO)

Everett Harris & Co. CA lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 0.2% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 6,497,372 shares of the company’s stock after selling 15,417 shares during the quarter. Novo Nordisk A/S comprises about 11.1% of Everett Harris & Co. CA’s portfolio, making the stock its 2nd largest holding. Everett Harris & Co. CA owned approximately 0.14% of Novo Nordisk A/S worth $834,263,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Cravens & Co Advisors LLC lifted its holdings in shares of Novo Nordisk A/S by 1.0% during the first quarter. Cravens & Co Advisors LLC now owns 8,250 shares of the company’s stock worth $1,059,000 after buying an additional 85 shares in the last quarter. U.S. Capital Wealth Advisors LLC boosted its holdings in Novo Nordisk A/S by 0.6% in the 4th quarter. U.S. Capital Wealth Advisors LLC now owns 15,421 shares of the company’s stock valued at $1,595,000 after purchasing an additional 90 shares during the period. Clarius Group LLC grew its position in shares of Novo Nordisk A/S by 0.5% during the 4th quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock worth $1,914,000 after purchasing an additional 93 shares in the last quarter. Tradewinds Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 2.0% during the fourth quarter. Tradewinds Capital Management LLC now owns 4,955 shares of the company’s stock worth $513,000 after purchasing an additional 95 shares during the period. Finally, Atlas Brown Inc. raised its position in shares of Novo Nordisk A/S by 2.5% in the first quarter. Atlas Brown Inc. now owns 3,823 shares of the company’s stock valued at $491,000 after buying an additional 95 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Argus raised their price objective on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. The Goldman Sachs Group initiated coverage on Novo Nordisk A/S in a research report on Thursday, May 30th. They issued a “buy” rating and a $156.00 price target on the stock. BMO Capital Markets reaffirmed an “outperform” rating and set a $163.00 price objective on shares of Novo Nordisk A/S in a research report on Tuesday, June 25th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Monday. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and an average target price of $145.67.

Novo Nordisk A/S Price Performance

Shares of NVO traded down $4.11 during mid-day trading on Thursday, reaching $138.87. The company had a trading volume of 7,455,753 shares, compared to its average volume of 3,491,449. The company has a market capitalization of $623.18 billion, a price-to-earnings ratio of 47.89, a P/E/G ratio of 1.41 and a beta of 0.41. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. The company’s 50 day simple moving average is $135.95 and its 200 day simple moving average is $124.47. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. The firm had revenue of $9.52 billion for the quarter, compared to analyst estimates of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. Analysts expect that Novo Nordisk A/S will post 3.44 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.